222 related articles for article (PubMed ID: 22857597)
21. A seven-marker signature and clinical outcome in malignant melanoma: a large-scale tissue-microarray study with two independent patient cohorts.
Meyer S; Fuchs TJ; Bosserhoff AK; Hofstädter F; Pauer A; Roth V; Buhmann JM; Moll I; Anagnostou N; Brandner JM; Ikenberg K; Moch H; Landthaler M; Vogt T; Wild PJ
PLoS One; 2012; 7(6):e38222. PubMed ID: 22685558
[TBL] [Abstract][Full Text] [Related]
22. Identification of a metastasis-specific MicroRNA signature in human colorectal cancer.
Hur K; Toiyama Y; Schetter AJ; Okugawa Y; Harris CC; Boland CR; Goel A
J Natl Cancer Inst; 2015 Mar; 107(3):. PubMed ID: 25663689
[TBL] [Abstract][Full Text] [Related]
23. Serum-based microRNA signature predicts relapse and therapeutic outcome of adjuvant chemotherapy in colorectal cancer patients.
Ji D; Qiao M; Yao Y; Li M; Chen H; Dong Q; Jia J; Cui X; Li Z; Xia J; Gu J
EBioMedicine; 2018 Sep; 35():189-197. PubMed ID: 30166271
[TBL] [Abstract][Full Text] [Related]
24. Serum exosomal microRNAs as potent circulating biomarkers for melanoma.
Tengda L; Shuping L; Mingli G; Jie G; Yun L; Weiwei Z; Anmei D
Melanoma Res; 2018 Aug; 28(4):295-303. PubMed ID: 29750752
[TBL] [Abstract][Full Text] [Related]
25. A direct plasma assay of circulating microRNA-210 of hypoxia can identify early systemic metastasis recurrence in melanoma patients.
Ono S; Oyama T; Lam S; Chong K; Foshag LJ; Hoon DS
Oncotarget; 2015 Mar; 6(9):7053-64. PubMed ID: 25749524
[TBL] [Abstract][Full Text] [Related]
26. Serum miRNAs, a potential prognosis marker of loco-regionally advanced nasopharyngeal carcinoma patients treated with CCRT.
Zhang Z; Huang J; Wang G; Jin F; Zheng J; Xiao H; Lei L; Luo J; Chen C
BMC Cancer; 2020 Mar; 20(1):183. PubMed ID: 32131777
[TBL] [Abstract][Full Text] [Related]
27. A four-marker signature of TNF-RII, TGF-α, TIMP-1 and CRP is prognostic of worse survival in high-risk surgically resected melanoma.
Tarhini AA; Lin Y; Yeku O; LaFramboise WA; Ashraf M; Sander C; Lee S; Kirkwood JM
J Transl Med; 2014 Jan; 12():19. PubMed ID: 24457057
[TBL] [Abstract][Full Text] [Related]
28. Signature of circulating microRNAs in patients with acute heart failure.
Ovchinnikova ES; Schmitter D; Vegter EL; Ter Maaten JM; Valente MA; Liu LC; van der Harst P; Pinto YM; de Boer RA; Meyer S; Teerlink JR; O'Connor CM; Metra M; Davison BA; Bloomfield DM; Cotter G; Cleland JG; Mebazaa A; Laribi S; Givertz MM; Ponikowski P; van der Meer P; van Veldhuisen DJ; Voors AA; Berezikov E
Eur J Heart Fail; 2016 Apr; 18(4):414-23. PubMed ID: 26345695
[TBL] [Abstract][Full Text] [Related]
29. microRNA expression profile in stage III colorectal cancer: circulating miR-18a and miR-29a as promising biomarkers.
Brunet Vega A; Pericay C; Moya I; Ferrer A; Dotor E; Pisa A; Casalots À; Serra-Aracil X; Oliva JC; Ruiz A; Saigí E
Oncol Rep; 2013 Jul; 30(1):320-6. PubMed ID: 23673725
[TBL] [Abstract][Full Text] [Related]
30. Serum miR-16: A Potential Biomarker for Predicting Melanoma Prognosis.
Guo S; Guo W; Li S; Dai W; Zhang N; Zhao T; Wang H; Ma J; Yi X; Ge R; Wang G; Gao T; Li C
J Invest Dermatol; 2016 May; 136(5):985-993. PubMed ID: 26829037
[TBL] [Abstract][Full Text] [Related]
31. Next generation sequencing profiling identifies miR-574-3p and miR-660-5p as potential novel prognostic markers for breast cancer.
Krishnan P; Ghosh S; Wang B; Li D; Narasimhan A; Berendt R; Graham K; Mackey JR; Kovalchuk O; Damaraju S
BMC Genomics; 2015 Sep; 16():735. PubMed ID: 26416693
[TBL] [Abstract][Full Text] [Related]
32. Genome-wide identification of a novel miRNA-based signature to predict recurrence in patients with gastric cancer.
Yang Y; Qu A; Zhao R; Hua M; Zhang X; Dong Z; Zheng G; Pan H; Wang H; Yang X; Zhang Y
Mol Oncol; 2018 Dec; 12(12):2072-2084. PubMed ID: 30242969
[TBL] [Abstract][Full Text] [Related]
33. Genome-wide Discovery and Identification of a Novel miRNA Signature for Recurrence Prediction in Stage II and III Colorectal Cancer.
Kandimalla R; Gao F; Matsuyama T; Ishikawa T; Uetake H; Takahashi N; Yamada Y; Becerra C; Kopetz S; Wang X; Goel A
Clin Cancer Res; 2018 Aug; 24(16):3867-3877. PubMed ID: 29514841
[No Abstract] [Full Text] [Related]
34. Identification of MicroRNAs associated with early relapse after nephrectomy in renal cell carcinoma patients.
Slaby O; Redova M; Poprach A; Nekvindova J; Iliev R; Radova L; Lakomy R; Svoboda M; Vyzula R
Genes Chromosomes Cancer; 2012 Jul; 51(7):707-16. PubMed ID: 22492545
[TBL] [Abstract][Full Text] [Related]
35. A plasma microRNA biomarker of melanoma as a personalised assessment of treatment response.
van Laar RK; Lincoln MT; van Laar BJ
Melanoma Res; 2019 Feb; 29(1):19-22. PubMed ID: 30320629
[TBL] [Abstract][Full Text] [Related]
36. Identification of a 7-microRNA signature in plasma as promising biomarker for nasopharyngeal carcinoma detection.
Zhang H; Zou X; Wu L; Zhang S; Wang T; Liu P; Zhu W; Zhu J
Cancer Med; 2020 Feb; 9(3):1230-1241. PubMed ID: 31856390
[TBL] [Abstract][Full Text] [Related]
37. Revisiting miRNA Association with Melanoma Recurrence and Metastasis from a Machine Learning Point of View.
Korfiati A; Grafanaki K; Kyriakopoulos GC; Skeparnias I; Georgiou S; Sakellaropoulos G; Stathopoulos C
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163222
[TBL] [Abstract][Full Text] [Related]
38. Sentinel Lymph Node Genes to Predict Prognosis in Node-Positive Melanoma Patients.
Hao H; Xiao D; Pan J; Qu J; Egger M; Waigel S; Sanders MA; Zacharias W; Rai SN; McMasters KM
Ann Surg Oncol; 2017 Jan; 24(1):108-116. PubMed ID: 27663566
[TBL] [Abstract][Full Text] [Related]
39. A 3-miRNA signature predicts survival of patients with hypopharyngeal squamous cell carcinoma after post-operative radiotherapy.
Xu X; Lu Z; Gross N; Li G; Zhang F; Lei D; Pan X
J Cell Mol Med; 2019 Dec; 23(12):8280-8291. PubMed ID: 31578816
[TBL] [Abstract][Full Text] [Related]
40. Tumor expression of miR-34a-3p is an independent predictor of recurrence in non-muscle-invasive bladder cancer and promising additional factor to improve predictive value of EORTC nomogram.
Juracek J; Stanik M; Vesela P; Radova L; Dolezel J; Svoboda M; Slaby O
Urol Oncol; 2019 Mar; 37(3):184.e1-184.e7. PubMed ID: 30446443
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
